Free tool
FAERS Monitor: Halaven
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 201532 or its brand name (Halaven, Eribulin Mesylate). Reports on generic versions are filed under their own applications.
Reports
3,739
Serious
3,465
93% of reports
Hospitalization
1,962
Death reported
663
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- neutropenia538
- malignant neoplasm progression383
- febrile neutropenia331
- myelosuppression318
- pyrexia216
- neuropathy peripheral214
- leukopenia208
- interstitial lung disease181
- white blood cell count decreased177
- neutrophil count decreased171
- fatigue159
- nausea157
- asthenia133
- pneumonia121
- decreased appetite116
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 74 |
| 2012 | 247 |
| 2013 | 213 |
| 2014 | 161 |
| 2015 | 334 |
| 2016 | 383 |
| 2017 | 354 |
| 2018 | 281 |
| 2019 | 255 |
| 2020 | 196 |
| 2021 | 243 |
| 2022 | 273 |
| 2023 | 337 |
| 2024 | 189 |
| 2025 | 120 |
| 2026 | 78 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,420 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelosuppressionSignal | 318 | 50.1 | 45.1 | 15,144 |
| febrile neutropeniaSignal | 331 | 28.2 | 25.4 | 8,643 |
| neutrophil count decreasedSignal | 171 | 23.7 | 20.5 | 3,686 |
| leukopeniaSignal | 208 | 23.5 | 20.6 | 4,447 |
| neutropeniaSignal | 538 | 22.3 | 20.7 | 10,975 |
| malignant neoplasm progressionSignal | 383 | 21.1 | 19.2 | 7,327 |
| interstitial lung diseaseSignal | 181 | 21.1 | 18.3 | 3,441 |
| neuropathy peripheralSignal | 214 | 12.7 | 11.1 | 2,296 |
| white blood cell count decreasedSignal | 177 | 9.2 | 8.0 | 1,290 |
| pyrexiaSignal | 216 | 3.5 | 3.1 | 392 |
| decreased appetiteSignal | 116 | 2.8 | 2.3 | 135 |
| pneumoniaSignal | 121 | 2.1 | 1.8 | 70 |
| asthenia | 133 | 2.0 | 1.7 | 66 |
| fatigue | 159 | 1.1 | 1.0 | 3 |
| nausea | 157 | 1.1 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.